Emerging markets are benefiting from enhanced healthcare infrastructure, boosting access to CMV diagnostics and treatments. Furthermore, advancements in personalized medicine and vaccine development, ...

Class H ( (HK:2630) ) has issued an announcement. Vigonvita Life Sciences Co., Ltd. has entered into a license agreement with Simcere Pharmaceutical Group Limited for new indications of its drug ...

Interested investors and guests of Cocrystal Pharma are welcome to attend the conference at a discounted rate. Please ...

Signs Master Services Agreement With Only Orphans Cote For NV-387 Orphan Drug Strategy. NanoViricides, Inc. (NYSE American: NNVC), a clinical stage global pioneer in broad-spectrum antivirals based on ...

Kochi: Ernakulam district sees the highest number of HIV cases in the state, with an average of 23 new cases reported every ...

Oseltamivir shifted the field by introducing a mechanism that traps the virus inside host cells, preventing release and ...

Salarius subsidiary Decoy Therapeutics’ influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico ...

SIGA Technologies, Inc. faces revenue uncertainty and dependency risks despite strong profits. Click for my updated look at ...

A completely new order of marine sponges has been found by researchers at the Museum of Evolution, Uppsala University. The ...

More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...

Merck & Co has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, paying $221.50 per share in cash to acquire all outstanding Cidara stock. The deal secures for Merck access to ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global ...